Skip to main content
BLSM
NASDAQ Life Sciences

OrbiMed Advisors Buys $10M in BlossomHill IPO at $16.00

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$16.24
Mkt Cap
$497.653M
52W Low
$15.97
52W High
$17.249
52W Position info
1.7% above low
Off High info
5.8% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BLSM is trading near its 52-week low of $15.97 (1.7% above the low).

Summary

OrbiMed Advisors LLC, a director-affiliated entity, bought $10 million of BlossomHill Therapeutics stock in the IPO at $16.00 per share, a significant insider purchase.


Key Events · Ownership and Investor Activity · BLSM

  • OrbiMed Buys $10M in IPO

    OrbiMed Advisors LLC purchased 625,000 shares at $16.00 per share for a total of $10,000,000 in BlossomHill's initial public offering on August 10, 2026.

  • Preferred Stock Conversion

    OrbiMed converted 2,089,279 shares of Series A and Series B Preferred Stock into common stock upon the IPO closing, with no additional consideration paid.

  • Post-Transaction Holdings

    After the purchase and conversion, OrbiMed's indirect holdings total 2,714,279 shares, representing a significant stake in the newly public company.

  • Insider Accumulation Signal

    This purchase adds to the accumulation signal from other insiders, including Cormorant Asset Management's $5 million purchase and the General Counsel's $74,700 purchase, all at the IPO price.


Analysis · BLSM · Life Sciences

A director-affiliated entity, OrbiMed Advisors LLC, purchased 625,000 shares for $10 million in BlossomHill's IPO at $16.00 per share. This is a significant open-market purchase by a key insider, representing roughly 2% of the company's market cap. The purchase follows the IPO pricing on August 7 and closing on August 10, and adds to the accumulation signal from other insiders. OrbiMed also converted 2,089,279 preferred shares into common stock upon the IPO, increasing its post-transaction holdings to 2,714,279 shares.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BLSM was trading at $16.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497.7M. The 52-week trading range was $15.97 to $17.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLSM - Latest Insights

BLSM
Nov 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.84
Real-time Price: $14.51 info
Change: -$0.330 (-2%) info
Market Cap: $461.199M info
BLSM
Nov 12, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.84
Real-time Price: $14.51 info
Change: -$0.330 (-2%) info
Market Cap: $461.199M info
BLSM
Sep 18, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.51
Real-time Price: $14.51 info
Change: -$12.00 (-45%) info
Market Cap: $461.199M info
BLSM
Sep 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $23.19
Real-time Price: $14.51 info
Change: -$8.68 (-37%) info
Market Cap: $461.199M info
BLSM
Aug 18, 2026, 4:53 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $16.10
Real-time Price: $14.51 info
Change: -$1.59 (-10%) info
Market Cap: $461.199M info